Skip to main content
. 2014 Nov 14;9(11):e112583. doi: 10.1371/journal.pone.0112583

Figure 3. Effect of von Willebrand factor on primary hemostasis in thrombocytopenic patients with liver cirrhosis.

Figure 3

Increased levels of vWF were associated with maintained normal primary hemostasis in patients with liver cirrhosis and reduced platelet count (<150/nL). vWF-antigen and vWF-activity were higher in patients with normal results for PFA-100 after measuring with Col-Epi and Col-ADP (A+B). Substitution of recombinant vWF (r-vWF) resulted in improved primary hemostasis as compared to unmodified samples (C). Addition of a 66-µg or 165-µg polyclonal anti-vWF-antibody levels led to prolonged closure times compared to unmodified control samples (D+E). Horizontal lines represent the upper limit of normal for closure times with Col-Epi or Col-ADP [**: P<0.01, *: P<0.05].